Home > Research > Publications & Outputs > Both the D-(+) and L-(-) enantiomers of nicotin...
View graph of relations

Both the D-(+) and L-(-) enantiomers of nicotine inhibit Aβ aggregation and cytotoxicity.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Both the D-(+) and L-(-) enantiomers of nicotine inhibit Aβ aggregation and cytotoxicity. / Moore, S. A.; Huckerby, T. N.; Gibson, G. L. et al.
In: Biochemistry, Vol. 43, No. 3, 01.2004, p. 819-826.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Moore SA, Huckerby TN, Gibson GL, Fullwood NJ, Turnbull I, Tabner BJ et al. Both the D-(+) and L-(-) enantiomers of nicotine inhibit Aβ aggregation and cytotoxicity. Biochemistry. 2004 Jan;43(3):819-826. doi: 10.1021/bi035728h

Author

Moore, S. A. ; Huckerby, T. N. ; Gibson, G. L. et al. / Both the D-(+) and L-(-) enantiomers of nicotine inhibit Aβ aggregation and cytotoxicity. In: Biochemistry. 2004 ; Vol. 43, No. 3. pp. 819-826.

Bibtex

@article{77e818ac24f8488daa9821b713ca99b3,
title = "Both the D-(+) and L-(-) enantiomers of nicotine inhibit Aβ aggregation and cytotoxicity.",
abstract = "The underlying cause of Alzheimer's disease is thought to be the aggregation of monomeric -amyloid (A), through a series of toxic oligomers, which forms the mature amyloid fibrils that accumulate at the center of senile plaques. It has been reported that L-(-)-nicotine prevents A aggregation and toxicity, and inhibits senile plaque formation. Previous NMR studies have suggested that this could be due to the specific binding of L-(-)-nicotine to histidine residues (His6, His13, and His14) in the peptide. Here, we have looked at the effects of both of the L-(-) and D-(+) optical enantiomers of nicotine on the aggregation and cytotoxicity of A(1-40). Surprisingly, both enantiomers inhibited aggregation of the peptide and reduced the toxic effects of the peptide on cells. In NMR studies with A(1-40), both enantiomers of nicotine were seen to interact with the three histidine residues. Overall, our data indicate that nicotine can delay A fibril formation and maintain a population of less toxic A species. This effect cannot be due to a highly specific binding interaction between nicotine and A, as previously thought, but could be due instead to weaker, relatively nonspecific binding, or to the antioxidant or metal chelating properties of nicotine. D-(+)-Nicotine, being biologically much less active than L-(-)-nicotine, might be a useful therapeutic agent.",
author = "Moore, {S. A.} and Huckerby, {T. N.} and Gibson, {G. L.} and Fullwood, {Nigel J.} and Iain Turnbull and Tabner, {Brian J.} and El-Agnaf, {Omar M. A.} and David Allsop",
year = "2004",
month = jan,
doi = "10.1021/bi035728h",
language = "English",
volume = "43",
pages = "819--826",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "3",

}

RIS

TY - JOUR

T1 - Both the D-(+) and L-(-) enantiomers of nicotine inhibit Aβ aggregation and cytotoxicity.

AU - Moore, S. A.

AU - Huckerby, T. N.

AU - Gibson, G. L.

AU - Fullwood, Nigel J.

AU - Turnbull, Iain

AU - Tabner, Brian J.

AU - El-Agnaf, Omar M. A.

AU - Allsop, David

PY - 2004/1

Y1 - 2004/1

N2 - The underlying cause of Alzheimer's disease is thought to be the aggregation of monomeric -amyloid (A), through a series of toxic oligomers, which forms the mature amyloid fibrils that accumulate at the center of senile plaques. It has been reported that L-(-)-nicotine prevents A aggregation and toxicity, and inhibits senile plaque formation. Previous NMR studies have suggested that this could be due to the specific binding of L-(-)-nicotine to histidine residues (His6, His13, and His14) in the peptide. Here, we have looked at the effects of both of the L-(-) and D-(+) optical enantiomers of nicotine on the aggregation and cytotoxicity of A(1-40). Surprisingly, both enantiomers inhibited aggregation of the peptide and reduced the toxic effects of the peptide on cells. In NMR studies with A(1-40), both enantiomers of nicotine were seen to interact with the three histidine residues. Overall, our data indicate that nicotine can delay A fibril formation and maintain a population of less toxic A species. This effect cannot be due to a highly specific binding interaction between nicotine and A, as previously thought, but could be due instead to weaker, relatively nonspecific binding, or to the antioxidant or metal chelating properties of nicotine. D-(+)-Nicotine, being biologically much less active than L-(-)-nicotine, might be a useful therapeutic agent.

AB - The underlying cause of Alzheimer's disease is thought to be the aggregation of monomeric -amyloid (A), through a series of toxic oligomers, which forms the mature amyloid fibrils that accumulate at the center of senile plaques. It has been reported that L-(-)-nicotine prevents A aggregation and toxicity, and inhibits senile plaque formation. Previous NMR studies have suggested that this could be due to the specific binding of L-(-)-nicotine to histidine residues (His6, His13, and His14) in the peptide. Here, we have looked at the effects of both of the L-(-) and D-(+) optical enantiomers of nicotine on the aggregation and cytotoxicity of A(1-40). Surprisingly, both enantiomers inhibited aggregation of the peptide and reduced the toxic effects of the peptide on cells. In NMR studies with A(1-40), both enantiomers of nicotine were seen to interact with the three histidine residues. Overall, our data indicate that nicotine can delay A fibril formation and maintain a population of less toxic A species. This effect cannot be due to a highly specific binding interaction between nicotine and A, as previously thought, but could be due instead to weaker, relatively nonspecific binding, or to the antioxidant or metal chelating properties of nicotine. D-(+)-Nicotine, being biologically much less active than L-(-)-nicotine, might be a useful therapeutic agent.

U2 - 10.1021/bi035728h

DO - 10.1021/bi035728h

M3 - Journal article

VL - 43

SP - 819

EP - 826

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 3

ER -